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We report on the location of 283 miRNAs in the human genome in relation to copy number changes in three distinct types of
tumours: prostate, bladder and colon. In prostate and colon tumours, we find miRNAs over-represented in regions with copy
number gain and under-represented in regions with copy number loss. Surprisingly this pattern appears to be reversed in bladder
cancer. We compared our miRNA copy number data to published miRNA expression data; unexpectedly, we did not find a
statistically significant relationship between miRNA copy number and expression level. This suggests that miRNA expression is
regulated through different mechanisms than mRNA expression.
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MicroRNAs (miRNAs) are small non-coding RNAs that are
conserved in sequences between distantly related organisms.
Mature miRNAs (B22 nucleotides) regulate gene expression by
targeting mRNAs for cleavage or translational inhibition (Bartel,
2004). They are known to be differently expressed in different
tissues. Moreover, several studies have suggested that miRNAs
might be involved in human tumorigenesis (Lu et al, 2005; Volinia
et al, 2006). Calin et al (2004) showed that miRNAs are frequently
located near genomic fragile sites as well as in cancer-associated
genomic regions. They screened PubMed for papers reporting any
cancer-related abnormalities and found that 98 of 186 miRNAs
were located in these regions. However, their study was not cancer
type specific and whether it generalises to specific cancers was not
discussed.
Lu et al (2005) reported on miRNAs expression profiles (217
miRNAs in 334 samples) and found that the majority of the
differentially expressed miRNAs were downregulated in tumour
samples compared to normal samples. More recently, Volinia et al
(2006) showed that miRNAs differently expressed in solid cancer
were mostly overexpressed. They evaluated the expression profiles
of 228 human miRNAs in 540 samples from six solid tumour types.
Based on these, they identified six tissue-specific cancer signatures
and proposed that the most common miRNA event in solid
tumours is gain of expression, while loss of expression is more
tissue-specific and less common.
In this study, we report on the location of miRNAs (n¼283) in
relation to copy number alterations in three specific cancer types,
prostate, bladder and colon. We use Affymetrix 10 and 50k SNP
arrays to identify genomic regions with abnormal copy numbers.
Further, we discuss our results in relation to the findings of Volinia
et al (2006) and Lu et al (2005).
MATERIALS AND METHODS
The GeneChipMapping 10k Early Access Array from Affymetrix
was applied to a set of 128 samples (113 normal samples and
15 colon adenocarcinomas) and the GeneChipMapping 50K
array was applied to 143 samples (72 normal samples, 41 prostate
tumours and 30 bladder tumours). SNP intensities were
extracted using the dChip software and subsequently all intensities
were normalised to facilitate comparisons between SNPs and
arrays, as described in Supplementary Material. Using this
procedure, the intensities in normal samples would be
centred on zero with a standard deviation (s.d.) of 1. We defined
seven groups of tumours: all prostate tumours (P1), prostate
tumours without metastasis (P2) or with metastasis (P3),
all bladder tumours (B1), bladder tumours in stage Ta (B2) or in
stage T1 (B3) and all colon tumours (C1). For each group of
tumours, an average intensity value for the group was calculated
for each SNP. From these, DNA copy numbers were estimated
using a threshold of 72 s.d. (above 2 s.d.: gain, below 2 s.d.:
loss, and otherwise two copies, i.e. normal copy number).
Subsequently, for each group of tumours, the genome was divided
into regions according to the DNA copy numbers (gain, loss,
normal) of consecutive SNPs. Genomic regions without any
SNP data were not considered (see Supplementary Material for
more information). Subsequently, it was investigated if the
distribution of genomic copy number alterations correlated with
the genomic distribution of 283 miRNAs (identified in the miRNA
registry (release 7.1), Griffiths-Jones, 2004; Griffiths-Jones et al,
2006).
RESULTS
Using the method and the predefined groups of tumours described
in Materials and Methods, we identified commonly occurring copy
number alterations in the groups. Genomic alterations are
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sgenerally coherent with previous findings (Zieger et al, 2005;
Andersen et al, 2006; Tørring et al, submitted).
Location of miRNAs
The number of miRNAs affected by the alterations was counted
and it was calculated if these numbers were unexpectedly high
or low (Table 1 and Figure 1). For both the colon tumours (C1)
and the prostate tumours (P1, P2 and P3), we observed an over-
representation in gain regions and an under-representation of
miRNAs in loss regions (Po0.00001) (Table 1 and Figure 1). As
regards the bladder tumours (B1 and B3), we observed a slight
under-representation of miRNAs in the gain regions (P¼0.0089;
Table 1).
Many miRNAs are located in close vicinity of each other
(distance o0.1Mb). After grouping miRNAs with distance
o0.1Mb into clusters, we ended up with 152 clusters and did
the analysis on those. We found the same features as before
(Table 1).
Comparisons between the different tumours
We compared the different tumour groups in order to investigate
whether the miRNAs were concentrated in loss or gain regions that
were shared between the groups. Tables S1 and S2 in Supplemen-
tary Material clearly indicate that regions are generally not shared
and that the findings above are not a consequence of shared
alterations between tumour types.
Genomic copy number alterations and miRNA expression
Volinia et al (2006) identified 39 overexpressed and six under-
expressed miRNAs (out of 228) in a sample of prostate tumours
and 21 overexpressed and one underexpressed miRNAs in a
sample of colon tumours. The differentially expressed miRNAs
were not statistically over-represented in the gain regions or loss
regions identified in the corresponding tumours in our samples
(P-values40.18; see Table 2).
DISCUSSION
In several papers, it has been shown that mRNA (or gene)
expression and gene copy number correlate (e.g. Benetkiewicz
et al, 2005; Tsafrir et al, 2006). It is natural to hypothesise that
miRNA expression also correlates with copy number. In this study,
we have reported on the location of miRNAs in relation to copy
number changes in three different cancers, prostate, colon and
Table 1 Analysis of copy numbers in relation to miRNA location in seven different groups of tumours
Number of miRNAs Number of miRNA clusters
Loss Normal Gain Loss Normal Gain
C1 (colon)
Obs. 66 172 38 47 72 28
Exp. 113.4 137.8 24.8 60.4 73.4 13.2
Size (in %) 41.1 49.9 9.0 41.1 49.9 9.0
P1 (prostate)
Obs. 35 175 71 21 102 27
Exp. 89.2 156.9 34.9 47.6 83.8 18.6
Size (in %) 31.7 55.8 12.4 31.7 55.8 12.4
P2 (without metastasis)
Obs. 14 257 10 12 132 6
Exp. 37.9 240.4 2.7 20.2 128.4 1.4
Size (in %) 13.5 85.6 0.9 13.5 85.6 0.9
P3 (with metastasis)
Obs. 28 115 138 16 92 42
Exp. 71.3 167.1 42.6 38.0 89.2 22.8
Size (in %) 25.4 59.5 15.2 25.4 59.5 15.2
B1 (bladder)
Obs. 42 228 11 33 111 6
Exp. 39.5 214.9 26.7 21.1 114.7 14.2
Size (in %) 14.1 76.5 9.5 14.1 76.5 9.5
B2 (stage Ta)
Obs. 7 274 0 5 145 0
Exp. 2.6 277.9 0.5 1.4 148.3 0.3
Size (in %) 0.9 98.9 0.2 0.9 98.9 0.2
B3 (stage T1)
Obs. 33 235 13 28 114 8
Exp. 32.5 219.2 29.2 17.4 117.0 15.6
Size (in %) 11.6 78.0 10.4 11.6 78.0 10.4
Obs.: observed numbers of miRNAs in the three region types (loss, gain, normal); Exp.: expected numbers of miRNAs assuming the numbers are proportional to the size of the
genome for a given region type; Size (in %): the size of the genome for a given region type in percentage. 7 miRNAs (five clusters) were excluded from the analysis of the colon
tumours and 2 miRNAs (two clusters) were excluded for the prostate and bladder tumours because they were not located near any SNPs (see Supplementary Material). The
three main groups are highlighted in bold. w
2 test for proportionality to the size of the region: unclustered miRNAs. C1, P1-3: Po0.00001, B1: P¼0.0089, B2: P¼0.056, B3:
P¼0.0085. Clustered miRNAs. C1, P1-3: Po0.0006, B1: P¼0.0054, B2: P¼0.028, B3: P¼0.010.
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sbladder. In the prostate and colon tumours, we observed an over-
representation in the gain regions and an under-representation of
miRNA genes in the loss regions. Generally the gain and the loss
regions were not shared between the two cancer types and miRNAs
were generally not located in shared regions. This pattern is
consistent with the hypothesis stated above and the findings in
Volinia et al (2006) that many miRNA were overexpressed in
prostate and colon tumours while few were underexpressed.
However, when scrutinising the locations of the differentially
expressed miRNAs it appears that these are not more (less)
frequently located in gain (loss) regions; contrary to what we
would expect if miRNA expression correlated with copy number.
Importantly, we found a different pattern of copy number
alterations in our set of bladder tumours, indicating that the
relationship between cancer-related regions and miRNA locations
is not straight-forward and probably cancer type specific.
Several explanations could accommodate for the discrepancies
between expression and copy numbers. First of all, the copy
numbers and the miRNA expressions values are obtained from
different samples and thus could show different conflicting
features. However, our samples as well as the samples in Volinia
et al (2006) are not believed to represent special groups or
subtypes of prostate and colon tumours, and general features
should thus be preserved between the samples.
Secondly, one could raise doubt about the validity of the data.
However, in a number of papers (Huang et al, 2004, 2006) it has
been shown that copy numbers reliably can be derived using SNP
arrays. The miRNA expression data set is one of a few public
Figure 1 Definition of loss, normal and gain regions and location of the miRNAs, using chromosome 9 as an example. For each SNP, the average of the
weighted signal intensities has been plotted. The dotted lines represent the cutoff of two standard deviations. The miRNA locations are denoted by a red
line or a number. Each number (here 2 or 3) corresponds to one cluster and gives the number of miRNAs contained in that cluster. The DNA status bar
summarises the information given by the plot. The red colour corresponds to the loss regions, the green to the gain regions, the grey to the normal regions
and the yellow to the non-investigated regions (no SNPs available) (see Materials and Methods and the Supplementary Material).
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savailable genome-wide data sets; in the only other data set that is
known to us (Lu et al, 2005) it is found that miRNA expression
consistently is downregulated in prostate, while the pattern in
colon is less clear.
Finally, miRNA expression could be regulated by mechanisms
very different from the mechanisms that regulate mRNA expres-
sion, resulting in a less obvious pattern between expression and
copy numbers. For example, miRNA expression could be
correlated to the expression of their numerous mRNA targets
(Griffiths-Jones, 2004), which might be located in different parts of
the genome and thus potentially have different copy-numbers.
The data is available upon request.
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Obs. 6 7 4
Exp. 4.1 10.6 2.3
Underexpressed
Obs. 0 1 0
Exp. 0.2 0.6 0.1
Prostate
Overexpressed
Obs. 6 24 5
Exp. 4.4 21.8 8.8
Underexpressed
Obs. 0 5 1
Exp. 0.7 3.7 1.5
Obs.: observed number of miRNAs; Exp.: expected number of miRNAs. P-values
above 18% for both cancer types.
Are microRNAs located in genomic regions associated with cancer?
P Lamy et al
1418
British Journal of Cancer (2006) 95(10), 1415–1418 & 2006 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s